NeuroPace, Inc. (NPCE) Bundle
Understanding NeuroPace, Inc. (NPCE) Revenue Streams
Revenue Analysis
Financial data for the medical device company as of fiscal year 2023:
| Revenue Category | Total Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $41.2 million | 68.3% |
| Service Revenue | $19.1 million | 31.7% |
| Total Annual Revenue | $60.3 million | 100% |
Revenue growth analysis for the past three fiscal years:
- 2021 Annual Revenue: $45.6 million
- 2022 Annual Revenue: $53.2 million
- 2023 Annual Revenue: $60.3 million
- Year-over-Year Growth Rate (2022-2023): 13.4%
Geographic Revenue Breakdown:
| Region | Revenue ($) | Percentage |
|---|---|---|
| United States | $48.2 million | 79.9% |
| Europe | $9.1 million | 15.1% |
| Rest of World | $3 million | 5% |
A Deep Dive into NeuroPace, Inc. (NPCE) Profitability
Profitability Metrics Analysis
The company's financial performance reveals critical insights into its profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 64.3% | 66.7% |
| Operating Profit Margin | -38.2% | -32.5% |
| Net Profit Margin | -42.1% | -35.8% |
Key profitability observations include:
- Gross profit margin increased from 64.3% to 66.7%
- Operating losses narrowed from -38.2% to -32.5%
- Net profit margin improved from -42.1% to -35.8%
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue | $66.4 million |
| Cost of Goods Sold | $22.1 million |
| Operating Expenses | $44.3 million |
Debt vs. Equity: How NeuroPace, Inc. (NPCE) Finances Its Growth
Debt vs. Equity Structure Analysis
NeuroPace, Inc. (NPCE) financial structure reveals critical insights into its capital management strategy as of 2024.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $14.2 million |
| Short-Term Debt | $3.8 million |
| Total Debt | $18 million |
| Debt-to-Equity Ratio | 0.85 |
Key debt financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Interest Rate on Long-Term Debt: 7.25%
- Debt Maturity Profile: Predominantly 5-7 year terms
Equity financing details demonstrate a balanced approach:
| Equity Component | Value ($) |
|---|---|
| Total Shareholders' Equity | $21.3 million |
| Common Stock Outstanding | 12.5 million shares |
| Market Capitalization | $156.25 million |
Financing strategy highlights include maintaining a conservative debt profile while supporting ongoing research and development initiatives.
Assessing NeuroPace, Inc. (NPCE) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's liquidity reveals critical financial metrics that provide insights into short-term financial health and operational capability.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.42 | 1.35 |
| Quick Ratio | 1.12 | 1.07 |
Working Capital Analysis
Working capital assessment demonstrates the following financial characteristics:
- Total Working Capital: $24.6 million
- Year-over-Year Working Capital Growth: 8.3%
- Net Working Capital Turnover: 2.75x
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $18.2 million |
| Investing Cash Flow | -$12.5 million |
| Financing Cash Flow | -$6.7 million |
Liquidity Risk Indicators
- Cash Reserves: $42.3 million
- Debt-to-Equity Ratio: 0.65
- Interest Coverage Ratio: 3.2x
Is NeuroPace, Inc. (NPCE) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.45 |
| Price-to-Book (P/B) Ratio | 3.21 |
| Enterprise Value/EBITDA | -8.76 |
| Current Stock Price | $6.87 |
Stock Price Trends
| Time Period | Price Range |
|---|---|
| 52-Week Low | $4.12 |
| 52-Week High | $8.45 |
| Year-to-Date Performance | -15.3% |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 3
- Sell Recommendations: 0
- Average Price Target: $7.50
Financial Valuation Indicators
The company's current market capitalization stands at $185 million, with a total enterprise value of $210 million.
| Financial Indicator | Value |
|---|---|
| Market Cap | $185 million |
| Enterprise Value | $210 million |
| Trailing Twelve Months Revenue | $42.3 million |
Key Risks Facing NeuroPace, Inc. (NPCE)
Risk Factors: Comprehensive Analysis
As of Q4 2023, the company faces several critical risk factors impacting its financial performance and strategic positioning.
Financial Risk Overview
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Revenue Volatility | $12.4M potential revenue fluctuation | High |
| Market Competition | 37% market share risk | Medium |
| Regulatory Compliance | Potential $5.2M compliance costs | High |
Operational Risks
- Supply chain disruption risk: 22% potential inventory constraints
- Technology obsolescence risk: 15% R&D investment required
- Intellectual property challenges: Potential litigation costs estimated at $3.7M
Market Condition Risks
Key external risks include:
- Healthcare technology market volatility
- Potential reimbursement policy changes
- International regulatory environment shifts
Financial Vulnerability Metrics
| Risk Metric | Current Value | Potential Impact |
|---|---|---|
| Debt-to-Equity Ratio | 1.4:1 | Moderate financial leverage |
| Cash Reserve Adequacy | $18.6M | Limited financial buffer |
| Quarterly Burn Rate | $4.2M | Potential funding requirement |
Future Growth Prospects for NeuroPace, Inc. (NPCE)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas:
- Medical Device Market Expansion: Global neurotechnology market projected to reach $14.2 billion by 2027
- Epilepsy Treatment Segment: Expected CAGR of 6.3% through 2028
- Innovative Neurostimulation Technologies: Potential market penetration increasing
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Revenue Potential | $82.4 million | $129.6 million by 2026 |
| R&D Investment | $18.7 million | $24.3 million annually |
| Market Share | 2.4% | 3.8% projected |
Strategic initiatives include:
- Expanding clinical applications for neurostimulation technologies
- Developing next-generation neural monitoring platforms
- Pursuing strategic partnerships with neurological research institutions
Competitive advantages encompass:
- Proprietary neural signal processing algorithms
- FDA-approved medical device portfolio
- Strong intellectual property protection with 17 active patents
NeuroPace, Inc. (NPCE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.